Salute e Benessere
Global Influenza Vaccine Market is Projected to Cross USD 14 Billion Mark by 2032 | DelveInsight
To read more about the latest highlights related to the influenza vaccine market, get a snapshot of the key highlights entailed in the
The influenza vaccine is a crucial preventive measure against the seasonal flu, which is caused by influenza viruses that mutate frequently. The vaccine is updated annually to protect against the most prevalent strains, typically including both influenza A and B viruses. It works by stimulating the immune system to produce antibodies that recognize and combat the virus, reducing the severity of illness and preventing complications such as pneumonia, hospitalization, and death. Influenza vaccines are available in different formulations, including inactivated (flu shots) and live attenuated (nasal spray) versions, catering to different age groups and medical conditions.
Widespread vaccination is essential for public health, especially for high-risk groups such as young children, elderly individuals, pregnant women, and those with chronic conditions like asthma or heart disease. The flu vaccine also helps reduce the burden on healthcare systems by lowering the number of flu-related hospitalizations and medical visits. While the vaccine's effectiveness varies from year to year, studies consistently show that it significantly reduces the risk of severe illness. Public health organizations, such as the WHO and CDC, recommend annual flu vaccination as the best strategy for preventing influenza outbreaks and maintaining community immunity.
North America held the largest share of the influenza vaccine market in 2024, driven by an increase in influenza cases across the region. In the assessment done by DelveInsight, the estimated total number of medical visits related to seasonal influenza in the US were 16 million in 2023. Type-specific cases of seasonal influenza were categorized into two types, Type A and Type B. The United States showed the highest cases of Type A compared to other 7MM countries. In 2023, the US, alone accounted for approximately 55% of total cases of Type A influenza. In 2023, the total vaccinated population was estimated to be 383 million in the 7MM. The highest vaccinated population was seen in the US.
Furthermore, regional government efforts to prevent and treat the flu are playing a key role. For instance, in July 2022 , GSK plc entered into a partnership with the Government of Canada to provide both pandemic and seasonal influenza vaccines for the protection of Canadian adults and children. As part of this agreement, GSK committed to supplying up to 80 million doses of pandemic influenza vaccine in the event of a pandemic, along with 16 million doses of seasonal influenza vaccine throughout the contract period. These are some of the factors contributing to the growth of the influenza vaccine market in the region.
To know more about why North America is leading the market growth in the influenza vaccine market, get a snapshot of the
The influenza vaccine market is influenced by several dynamics, primarily driven by in vaccine development. Annual flu seasons create a constant demand for vaccines, as different strains of the virus circulate each year. This necessitates the formulation of updated vaccines, which boosts the demand for production. Leading vaccine manufacturers, such as , dominate the market, but competition is emerging from smaller biotech firms focusing on , such as mRNA technology.
The market is also impacted by , especially during pandemic outbreaks or seasonal flu spikes. Countries around the world, particularly in regions with a higher prevalence of flu-related hospitalizations and deaths, . The rise in vaccination awareness, bolstered by media campaigns and educational efforts, has further stimulated vaccine uptake. Additionally, , such as GAVI and the World Health Organization's support for immunization in low-income countries, are increasing access to vaccines and expanding market reach.
Vaccine technology plays a critical role in market dynamics. is being replaced by cell-based and recombinant DNA technologies, which are faster and more scalable. The , as seen in the COVID-19 pandemic, has introduced a new era of possibilities for influenza vaccines, promising better efficacy and faster production timelines. However, challenges remain, including the , especially for mRNA vaccines, which may limit their accessibility in certain markets.
Finally, are shaping the market. In developed countries, the elderly and those with chronic conditions are the primary recipients of the flu vaccine, driving demand. Meanwhile, the among healthy adults and children is expanding the market base. At the same time, factors like present ongoing challenges. Nevertheless, continued advancements in vaccine research and public health policy are expected to drive growth in the global influenza vaccine market.
Get a sneak peek at the influenza vaccine market dynamics @
Which MedTech key players in the influenza vaccine market are set to emerge as the trendsetter explore @
Interested in knowing the influenza vaccine market by 2032? Click to get a snapshot of the
report delivers an in-depth understanding of market trends, market drivers, market barriers, and key vaccine adjuvants companies, including among others.
report delivers an in-depth understanding of market trends, market drivers, market barriers, and key vaccines companies, including among others.
report delivers an in-depth understanding of market trends, market drivers, market barriers, and key seasonal influenza companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key influenza companies, including among others.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Shruti Thakur
info@delveinsight.com
+14699457679
https://www.delveinsight.com/medical-devices
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/global-influenza-vaccine-market-is-projected-to-cross-usd-14-billion-mark-by-2032--delveinsight-302381044.html